BC
PTCT icon

Brookfield Corp’s PTC Therapeutics PTCT Stock Holding History

Brookfield Corp’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,795
Closed -$561K – 430
2023
Q2 		$561K Sell
13,795
-90,535
-87% -$4.43M ﹤0.01% 497
2023
Q1 		$5.05M Sell
104,330
-5,429
-5% -$248K 0.02% 289
2022
Q4 		$4.19M Buy
109,759
+41,024
+60% +$1.71M 0.02% 290
2022
Q3 		$3.45M Buy
68,735
+34,150
+99% +$1.67M 0.01% 339
2022
Q2 		$1.39M Sell
34,585
-8,425
-20% -$295K 0.01% 470
2022
Q1 		$1.6M Buy
+43,010
New +$1.66M 0.01% 429

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Brookfield Corp's PTCT Position: Q3 2023 in Review

Brookfield Corp sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 13,795 shares — an estimated $561K sold.

Brookfield Corp first reported a position in PTCT in Q1 2022 and held it in 6 quarters. The position peaked at $5.05M in Q1 2023. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Brookfield Corp reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 13,795 PTC Therapeutics shares in Q3 2023, an estimated $561K.
  • Brookfield Corp first reported a position in PTC Therapeutics in Q1 2022 and held it in 6 quarters.
  • Brookfield Corp's PTC Therapeutics position peaked at $5.05M in Q1 2023.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.